Search

Your search keyword '"Cifkova R."' showing total 406 results

Search Constraints

Start Over You searched for: Author "Cifkova R." Remove constraint Author: "Cifkova R."
406 results on '"Cifkova R."'

Search Results

1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

2. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

6. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants

13. Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331 288 participants

15. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

16. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

18. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

21. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

22. Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a survey from the European Society of Cardiology

23. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

24. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

25. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

26. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine

27. National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio:a pooled analysis of 458 population-based studies in Asian and Western countries

29. Guía europea de prevención cardiovascular en la práctica clínica. Tercer grupo de trabajo de las sociedades europeas y otras sociedades sobre prevención cardiovascular en la práctica clínica: Constituido por representantes de 8 sociedades y expertos invitados

30. Polygenic risk scores predict diabetic complications and their response to therapy

32. 2018 ESC/ESH guidelines for the diagnosis and treatment of arterial hypertension: The Task Force for the Diagnosis and Treatment of Arterial Hypertension of the European Society of Cardiology (ESC) and of the European Society of Hypertension (ESH)

34. National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: an analysis of trends in Asian and Western countries

35. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry

36. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

37. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial

38. Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Tercer grupo de trabajo de las sociedades europeas y otras sociedades sobre prevención cardiovascular en la práctica clínica (constituido por representantes de ocho sociedades y expertos invitados)

40. Evolocumab and clinical outcomes in patients with cardiovascular disease

41. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: A pooled analysis of 1018 population-based measurement studies with 88.6 million participants

44. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

45. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults

47. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants

48. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants

49. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack

50. 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*

Catalog

Books, media, physical & digital resources